Lv11
80 积分 2024-07-04 加入
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types
11小时前
已关闭
Quantitative and dynamic ctDNA as a biomarker of response and survival in lung squamous cancer patients receiving immunochemotherapy or chemotherapy alone
2天前
已关闭
PD1 × VEGF blocking bispecifics for cancer draw big backing
10天前
已关闭
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
22天前
已完结
Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy
1个月前
已完结
Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis
1个月前
已完结
Management of Brain Metastases in Non–Small-Cell Lung Cancer
1个月前
已完结
Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison
1个月前
已完结
Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System
1个月前
已完结
PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice
1个月前
已完结
皖公网安备34019202002308
